Advanced Cell Therapy product release containing CAR-T cells
DOI:
https://doi.org/10.46765/2675-374X.2022v3n1p156Keywords:
CAR-T cells, product release, potency test, sterility, safetyAbstract
Manufacturing of customized gene or cell therapy products such as CAR-T cells is complex and depends on release tests and exams that can attest to a consistent quality standard for each product. The quality of CAR-T cell products is subject to donor variation, but also includes the manufacturing environment, as well as the quality and availability of materials and reagents. Quality must be carefully monitored and integrated into the manufacturing process.
Downloads
Published
04/24/2022
How to Cite
Preto de Godoy, J., Nassif Kerbauy, L., Melo Alves Paiva, R., Tiemi Kondo, A., Keith Okamoto, O., & Mauro Kutner, J. (2022). Advanced Cell Therapy product release containing CAR-T cells. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(1), 156. https://doi.org/10.46765/2675-374X.2022v3n1p156
Issue
Section
Original article
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
